These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11161962)

  • 1. Design and interpretation of studies of the risk of cancer and other long-term morbidity and mortality after growth hormone treatment.
    Swerdlow AJ
    Growth Horm IGF Res; 2000 Dec; 10(6):318-23. PubMed ID: 11161962
    [No Abstract]   [Full Text] [Related]  

  • 2. Does growth hormone cause cancer?
    Jenkins PJ; Mukherjee A; Shalet SM
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):115-21. PubMed ID: 16430706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone.
    Swerdlow AJ; Cooke R; Albertsson-Wikland K; Borgström B; Butler G; Cianfarani S; Clayton P; Coste J; Deodati A; Ecosse E; Gausche R; Giacomozzi C; Kiess W; Hokken-Koelega AC; Kuehni CE; Landier F; Maes M; Mullis PE; Pfaffle R; Sävendahl L; Sommer G; Thomas M; Tollerfield S; Zandwijken GR; Carel JC
    Horm Res Paediatr; 2015; 84(3):172-83. PubMed ID: 26227295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients.
    Mills JL; Schonberger LB; Wysowski DK; Brown P; Durako SJ; Cox C; Kong F; Fradkin JE
    J Pediatr; 2004 Apr; 144(4):430-6. PubMed ID: 15069388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Methodology and long-term follow-up of drug induced side effects in children (cancer, leukemia, AIDS, growth hormone)].
    Hoog-Labouret N; Lassale C; Eschwege E;
    Therapie; 2002; 57(4):322-8. PubMed ID: 12422552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of growth hormone replacement therapy in adults.
    Toogood A
    Expert Opin Drug Saf; 2005 Nov; 4(6):1069-82. PubMed ID: 16255665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long term mortality of five-year survivors of childhood cancer in Rhône-Alpes region].
    Trombert-Paviot B; Frappaz D; Casagranda L; Plantaz D; Bertrand Y; Stephan JL; Berger C; Freycon F
    Rev Epidemiol Sante Publique; 2008 Dec; 56(6):383-90. PubMed ID: 19013040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine sequelae in survivors of childhood cancer.
    Oberfield SE; Sklar CA
    Adolesc Med; 2002 Feb; 13(1):161-9, viii. PubMed ID: 11841962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term surveillance of growth hormone therapy.
    Rosenfeld RG; Cohen P; Robison LL; Bercu BB; Clayton P; Hoffman AR; Radovick S; Saenger P; Savage MO; Wit JM
    J Clin Endocrinol Metab; 2012 Jan; 97(1):68-72. PubMed ID: 22174422
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of hypopituitary children.
    Cutler GB; Chipman JJ
    J Pediatr; 2004 Apr; 144(4):415-6. PubMed ID: 15069384
    [No Abstract]   [Full Text] [Related]  

  • 11. Growth hormone and cancer: are we asking the right questions?*.
    Holly J; Perks C
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):122-4. PubMed ID: 16430707
    [No Abstract]   [Full Text] [Related]  

  • 12. Follow-up of long-term cancer survivors in the Nordic countries.
    Nord C; Ganz PA; Aziz N; Fosså SD
    Acta Oncol; 2007; 46(4):433-40. PubMed ID: 17497309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term cause-specific mortality among five-year survivors of childhood cancer.
    Cardous-Ubbink MC; Heinen RC; Langeveld NE; Bakker PJ; Voûte PA; Caron HN; van Leeuwen FE
    Pediatr Blood Cancer; 2004 Jun; 42(7):563-73. PubMed ID: 15127410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replacement therapy with growth hormone and pituitary tumor recurrence: the relevance of the problem.
    Losa M; Gatti E; Rossini A; Lanzi R
    J Endocrinol Invest; 2008 Sep; 31(9 Suppl):75-8. PubMed ID: 19020392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics.
    Calle EE; Rodriguez C; Jacobs EJ; Almon ML; Chao A; McCullough ML; Feigelson HS; Thun MJ
    Cancer; 2002 Jan; 94(2):500-11. PubMed ID: 11900235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics.
    Calle EE; Rodriguez C; Jacobs EJ; Almon ML; Chao A; McCullough ML; Feigelson HS; Thun MJ
    Cancer; 2002 May; 94(9):2490-501. PubMed ID: 12015775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature.
    Ranke MB; Lindberg A; Price DA; Darendeliler F; Albertsson-Wikland K; Wilton P; Reiter EO;
    Horm Res; 2007; 68(2):53-62. PubMed ID: 17228181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Still no indications that the treatment of growth hormone deficient adults with growth hormones is unsafe].
    Janssen JA; Visser WE; van der Lely AJ
    Ned Tijdschr Geneeskd; 2004 Jul; 148(30):1486-9. PubMed ID: 15481571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults.
    Cenci MC; Conceição FL; Soares DV; Spina LD; Brasil RR; Lobo PM; Michmacher E; Vaisman M
    Metabolism; 2008 Jan; 57(1):121-9. PubMed ID: 18078869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of growth hormone treatment on metabolic and cardiovascular risk factors is similar in preterm and term short, small for gestational age children.
    de Kort SW; Willemsen RH; van der Kaay DC; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):65-73. PubMed ID: 19094073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.